Technical Data
c-erbB2, p185 (HER2, neu Receptor) (BSA & Azide Free)
c-erbB-2 is a membrane-associated oncoprotein having considerable sequence homology to EGFR. C-erbB-2 is the second member of the EGF receptor tyrosine kinase family of growth factor receptors. Overexpression of c-erbB-2/HER-2 is reportedly a marker of poor prognosis in node-positive and in defined subsets of node-negative breast cancer. Elevated levels of c-erbB-2/HER-2 has also been implicated in response to chemotherapy.

Suitable for ELISA, Immunoprecipitation, Western Blot and Immunohistochemistry. Other applications have not been tested.

Recommended Dilutions:
Immunoprecipitation: 10ug/mg protein lysate. Use Protein A.
Western Blot: 5-10ug/ml for 2 hours at RT
Immunohistochemistry (Formalin/paraffin): 2.5-5ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 minutes followed by cooling at RT for 20 minutes.
Optimal dilutions to be determined by the researcher.

Positive Control:
SKBR-3 cells, T47D cells or breast carcinomas.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
500ug-20CBlue IceHumanRabbit
Synthetic peptide derived from the C-terminus of human c-erbB-2/HER-2 protein. Sequence is identical in rat neu protein. Cellular Localization: Cell membrane. Epitope: C-terminal.
Purified by Protein A affinity chromatography.
Supplied as a liquid in PBS, pH 7.4. No stablilizing proteins and no preservatives added. Available with BSA and sodium azide. See C0015.
Recognizes wild and mutant (oncogenic) forms of human c-erbB-2 protein (185kD). Species Crossreactivity: monkey, rat and mouse.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Gullick, W.J., et al., Int. J. Cancer 40(2): 246-254 (1987). 2. Gasparini, G., et al., Eur. J. Cancer 30A(1): 16-22 (1994). 3. Coombs, L.M., et al., J. Path. 169(1): 35-42 (1993). 4. Schlegel, J., et al., Acta Neuropathologica 86(5): 473-479 (1993). 5. Soomro, S., et al., Int. J. Cancer 55(1): 63-65 (1993). 6. Allred, D.C., et al., Human Path. 23(9): 974-979 (1992). 7. Allred, D.C., et al., J. Clin. Oncol. 10(4): 599-605 (1992). 8. Gasparini, G., et al., J. Clin. Oncol. 10(5): 686-695 (1992). 9. Hilton, D.A. & West, K.P., J. Clin. Path. 45(5): 454-456 (1992). 10. Hitchcock, A., et al., Am. J. Surg. Path. 16(1): 58-61 (1992). 11. Molina, R., et al., Anticancer Res. 12: 1965-1971 (1992). 12. Noguchi, M., et al., Cancer 69(12): 2953-2960 (1992). 13. Schroeter, C.A., et al., Br. J. Cancer 66(4): 728-734 (1992). 14. Allred, D.C., Tandon, A.K., Clark, G.M., McGuire, W.L.: HER-2/neu oncogene amplification and expression in human mammary carcinoma. Biochemical and Molecular Aspects of Selected Cancer, Vol. I (Chapter 3). Pretlow, T.G., Pretlow, T.P. (eds.), Academic Press 75-97 (1991). 15. Barnes, D.M., et al., Breast Cancer Res. and Treat. 18(1): 11-17 (1991). 16. Coombs, L.M., et al., Brit. J. Cancer 63(4): 601-608 (1991). 17. Hainsworth, P.J., et al., Eur. J. Surg. Oncol. 17(1): 9-15 (1991). 18. Lovekin, C., et al., [published erratum appears in Br. J. Cancer 64(1): 202 (1991)]. Br. J. Cancer 63(3): 439-443 (1991). 19. McCann, A.H., et al., Cancer Res. 51(12): 3296-3303 (1991). 20. Soomro, S., et al., J. Clin. Path. 44(3): 211-214 (1991). 21. Winstanley, J., et al., Br. J. Cancer 63(3): 447-450 (1991). 22. Bartkova, J., et al., Human Path. 21(11): 1164-1167 (1990). 23. Borg, A., et al., Cancer Res. 50: 4332-4337 (1990). 24. Haldane, J.S., et al., J. Path. 162(3): 231-237 (1990). 25. Hall, P.A., et al., J. Path. 161(3): 195-200 (1990). 26. McCann, A., et al., Cancer 65(1): 88-92 (1990). 27. Ramachandra, S., et al., J. Path. 161(1): 7-14 (1990). 28. Richner, J., et al., Ann. Oncol. 1(4): 263-268 (1990). 29. Gullick, W.J., et al., Int. J. Cancer 40(2): 246-54 (1987, Aug 15).